Charles Petty (Charlie)

Charlie is co-head of Intercept, a $500 million fund launched from Stripe's Public Goods team to reduce the burden of respiratory infections. Charlie was previously a Managing Director at the Global Health Investment Corporation and a co-founder of Adjuvant Capital. Before his career in public health investing, he was a private equity investor at Artemis Capital Partners and Axia Capital. Charlie started his career at Haiti’s largest microfinance bank, Sevis Finansye Fonkoze.

​

Charlie has led or participated in investments in Curevo Vaccine (acquired by Eli Lilly), Vaccine Company (acquired by Eli Lilly), Alydia Health (acquired by Merck), Iantech (acquired by Carl Zeiss Meditec), Eubiologics (Kosdaq:206650), MDGH (PRV), Terrestrial Bio, Foundry, Centivax, Excision Biotherapeutics, Codagnix, Endpoint Health, Cytovale, and Monod Bio. He currently serves on the boards of Curevo Vaccine, Aceris Biosciences, Blueprint Biosecurity, ProEquip, and the Mirror Biology Dialogues Fund.